Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medipixel’s flagship product MPXA uses deep learning to provide real-time, automated quantitative analysis of coronary arteries during interventional procedures. It delivers results in under two seconds with high accuracy (vessel segmentation F1 score of 0.91), supporting rapid clinical decision-making for physicians. The solution has been recognized globally for its innovation and impact on digital health and was named one of the "World's Best Digital Health Companies 2024" by Newsweek.
Clinical validation data includes high accuracy metrics but detailed peer-reviewed clinical trial outcomes are not specified in public sources.
The company has won multiple awards including the top prize at the 2023 Asia Pacific Accelerator program by MedTech Innovator/APACMed.
MPXA has been adopted or piloted in several hospitals internationally as part of global expansion efforts beyond South Korea and India.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medipixel.